Plasma Neutralization of the SARS-CoV-2 Omicron Variant

Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals

Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Hoffmann, M., Kleine-Weber, H., & Pöhlmann, S. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.022 · Cited by 1,852

Evolution of antibody immunity to SARS-CoV-2

Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2571-7 · Cited by 1,349

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic

Karim, S. S. A., & Karim, Q. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02758-6 · Cited by 1,302

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020) · Science · doi:10.1126/science.abd0831 · Cited by 1,253

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann, H. H., Barnes, C. O., Cipolla, M., Ramos, V., et al. (2021) · Nature · doi:10.1038/s41586-021-03696-9 · Cited by 721

Effect of booster vaccination against Delta and Omicron SARS-CoV-2 variants in Iceland

Norddahl, G. L., Melsted, P., Gunnarsdóttir, K., Halldorsson, G. H., Olafsdottir, T. A., Gylfason, A., Kristjánsson, M., Magnússon, Ó. Þ., Sulem, P., Gudbjartsson, D. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33076-4 · Cited by 7

Antibody Response of Heterologous vs Homologous mRNA Vaccine Boosters Against the SARS-CoV-2 Omicron Variant: Interim Results from the PRIBIVAC Study, A Randomized Clinical TrialPreprint

Poh, X. Y., Tan, C. W., Lee, I. R., Chavatte, J., Ong, S. W. X., Prince, T., Hartley, C. S., Yeoh, A. Y.-Y., Rao, S., Chia, P. Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4056669 · Cited by 7

A Large-Scale Dataset of Twitter Chatter about Online Learning during the Current COVID-19 Omicron WavePreprint

Thakur, N. (2022) · doi:10.36227/techrxiv.20363742.v1 · Cited by 7

A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ T cell profile

Sannier, G., Nicolas, A., Dubé, M., Marchitto, L., Nayrac, M., Tastet, O., Chatterjee, D., Tauzin, A., Lima-Barbosa, R., Laporte, M., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100955 · Cited by 6

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone

da Silva, E. S., Servais, J.-Y., Kohnen, M., Arendt, V., Gilson, G., Staub, T., Seguin‐Devaux, C., & Perez-Bercoff, D. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45020112 · Cited by 6

First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial

Poh, X. Y., Lee, I. R., Tan, C. W., Chavatte, J., Fong, S., Goh, Y. S., Rouers, A., Wong, N., Torres‐Ruesta, A., Mah, S. Y. Y., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105275 · Cited by 6

Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study

Fujitani, M., Lu, X., Shinnakasu, R., Inoue, T., Kidani, Y., Seki, N. M., Ishida, S., Mitsuki, S., Ishihara, T., Aoki, M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1550279 · Cited by 8

The Future of SARS-CoV-2 Vaccination.

Bachmann, M. F., Mohsen, M. O., & Speiser, D. E. (2022) · doi:10.48350/176180 · Cited by 6

Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern

Almanza, G., Clark, A. E., Kouznetsova, V. L., Olmedillas, E., Castro, A., Tsigelny, I. F., Wu, Y., Gao, G. F., Leibel, S. L., Bray, W. A., et al. (2022) · PLoS Pathogens · doi:10.1371/journal.ppat.1010686 · Cited by 5

Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents

Puthanakit, T., Nantanee, R., Jaru-Ampornpan, P., Chantasrisawad, N., Sophonphan, J., Meepuksom, T., Jupimai, T., Sodsai, P., Anugulruengkitt, S., & Hirankarn, N. (2022) · Vaccine X · doi:10.1016/j.jvacx.2022.100211 · Cited by 4

Using machine learning models to predict the duration of the recovery of COVID-19 patients hospitalized in Fangcang shelter hospital during the Omicron BA. 2.2 pandemic

Xu, Y., Ye, W., Song, Q., Shen, L., Liu, Y., Yuhang, G., Liu, G., Wu, H., Wang, X., Sun, X., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1001801 · Cited by 6

Kinetics and ability of binding antibody and surrogate virus neutralization tests to predict neutralizing antibodies against the SARS-CoV-2 Omicron variant following BNT162b2 booster administration

Simon, G., Favresse, J., Gillot, C., Closset, M., Catry, É., Dogné, J., Douxfils, J., Wieërs, G., & Bayart, J. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1258 · Cited by 7

Distinct Clinical Presentations and Outcomes of Hospitalized Adults with the SARS-CoV-2 Infection Occurring during the Omicron Variant Surge

Niu, J., Kim, M., Jalal, A. T., Goldberg, J. E., Martinez, E. M. A., Moscoso, N. P. S., Rubio-Gomez, H., Mayer, D., Visbal, A., Sareli, C., et al. (2023) · Healthcare · doi:10.3390/healthcare11121703 · Cited by 6

mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer

Song, N., Chakravarthy, K. B., Jeon, H., Bolyard, C. M., Reynolds, K., Weller, K. P., Reisinger, S. A., Wang, Y., Li, A., Jiang, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007922 · Cited by 6

Longitudinal Analysis of Coronavirus-Neutralizing Activity in COVID-19 Patients

Hastert, F. D., Henß, L., von Rhein, C., Gerbeth, J., Wieters, I., Borgans, F., Khodamoradi, Y., Zacharowski, K. D., Rohde, G. G. U., Vehreschild, M. J. G. T., et al. (2022) · Viruses · doi:10.3390/v14050882 · Cited by 6

Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2

Barbier, M., Lee, K. S., Vikharankar, M. S., Rajpathak, S. N., Kadam, N., Wong, T. Y., Russ, B. P., Cyphert, H. A., Miller, O. A., Rader, N. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.948431 · Cited by 6

Clinical grade ACE2 effectively inhibits SARS-CoV-2 Omicron infectionsPreprint

Monteil, V., Devignot, S., Klingström, J., Thålin, C., Kellner, M. J., Christ, W., Havervall, S., Mereiter, S., Knapp, S., Montserrat, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.25.474113 · Cited by 6

Efficient Neutralization of SARS-CoV-2 Omicron and Other VOCs by a Broad Spectrum Antibody 8G3Preprint

Ma, H., Tseng, C.-T. K., Zong, H., Liao, Y., Ke, Y., Tang, H., Wang, L., Wang, Z., He, Y., Chang, Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.25.482049 · Cited by 6

Titers of antibodies the receptor-binding domain (RBD) of ancestral SARS-CoV-2 are predictive for levels of neutralizing antibodies to multiple variantsPreprint

Tran, T. T., Vaage, E. B., Mehta, A., Chopra, A., Kolderup, A., Anthi, A. K., König, M. S. S., Nygaard, G. O., Lind, A., Müller, F., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.26.484261 · Cited by 6

Evolution of long-term vaccine induced and hybrid immunity in healthcare workers after different COVID-19 vaccination regimens: a longitudinal observational cohort studyPreprint

Moore, S. C., Kronsteiner, B., Longet, S., Adele, S., Deeks, A. S., Liu, C., Dejnirattisai, W., Silva-Reyes, L., Meardon, N., Faustini, S. E., et al. (2022) · medRxiv · doi:10.1101/2022.06.06.22275865 · Cited by 6

Severity of Omicron (B.1.1.529) and Delta (B.1.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort studyPreprint

Hyams, C. J., Challen, R., Marlow, R. D., Nguyen, J. L., Begier, E. M., Southern, J., King, J., Morley, A., Kinney, J., Clout, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1808133/v1 · Cited by 6

Germinal Center Response to mRNA Vaccination and Impact of Immunological Imprinting on Subsequent Vaccination

Kim, W. (2024) · Immune Network · doi:10.4110/in.2024.24.e28 · Cited by 5

Research Progress on the Structure and Function, Immune Escape Mechanism, Antiviral Drug Development Methods, and Clinical Use of SARS-CoV-2 Mpro

Ren, J., Zhang, Z., Xia, Y., Zhao, D., Li, D., & Zhang, S. (2025) · Molecules · doi:10.3390/molecules30020351 · Cited by 6

SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol

Bachelet, V. C., Silva-Ayarza, I., Lizana, F. J., Patricio Gomolan, G., Silva-Villalobos, D., & Navarrete, M. S. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061345 · Cited by 5

A systematic review of the safety and efficacy of convalescent plasma or immunoglobulin treatment for people with severe respiratory viral infections due to coronaviruses or influenza

Kimber, C., Lamikanra, A., Geneen, L. J., Sandercock, J., Doree, C. J., Valk, S. J., & Estcourt, L. J. (2022) · Transfusion Medicine · doi:10.1111/tme.12942 · Cited by 5

A comparative analysis exposes an amplification delay distinctive to SARS-CoV-2 Omicron variants of clinical and public health relevance

Brown, K. L., Ceci, A., Roby, C. D., Briggs, R., Ziolo, D., Korba, R., Mejia, R., Kelly, S., TONEY, D. M., Friedlander, M. J., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2154617 · Cited by 5

Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine

Qiu, S., Chen, Z., Zhu, A., Zeng, Q., Liu, H., Liu, X., Ye, F., Jin, Y., Wu, J., Yang, C., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01345-3 · Cited by 5

Magnitude and Duration of Serum Neutralizing Antibody Titers Induced by a Third mRNA COVID-19 Vaccination against Omicron BA.1 in Older Individuals

Park, J.-S., Jeon, J., Um, J., Choi, Y. Y., Kim, M.-K., Lee, K., Sung, H. K., Jang, H., Chin, B. S., Kim, C. K., et al. (2024) · Infection and Chemotherapy · doi:10.3947/ic.2023.0057 · Cited by 5

Absence of neutralizing antibodies against the Omicron SARS-CoV-2 variant in convalescent sera from individuals infected with the ancestral SARS-CoV-2 virus or its Gamma variant

Villas-Boas, L. S., de Paula, A. V., da Silva, A. R., Paião, H. G. O., Tozetto‐Mendoza, T. R., Manuli, E. R., Leal, F. E., Ferraz, A. D. B. C., Sabino, É. C., Bierrenbach, A. L., et al. (2022) · Clinics · doi:10.1016/j.clinsp.2022.100068 · Cited by 5

Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]

Poh, X. Y., Lee, I. R., Lim, C., Teo, J., Rao, S., Chia, P. Y., Ong, S. W. X., Lee, T. H., Kline, S., Ng, L. F. P., et al. (2022) · Trials · doi:10.1186/s13063-022-06345-2 · Cited by 6

Molecular mechanisms responsible for SARS-CoV-2 antibody waning and vaccine escape in Omicron sublineages BA.4 and BA.5

Hewins, B., Richardson, C., Rubino, S., Kelvin, A. A., Ostadgavahi, A. T., & Kelvin, D. J. (2022) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.17010 · Cited by 5

Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19

Liu, W.-D., Wang, J., Chao, T., Ieong, S., Tsai, Y., Kuo, P.-H., Tsai, M.-J., Chen, Y.-J., Li, G.-C., Ho, S., et al. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.11.015 · Cited by 5

Heteromultimeric sarbecovirus receptor binding domain immunogens primarily generate variant-specific neutralizing antibodies

Zang, T. M., Kuffour, E. O., Baharani, V. A., Canis, M., Schmidt, F., DaSilva, J., Lercher, A., Chaudhary, P., Hoffmann, H.-H., Gazumyan, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2317367120 · Cited by 4

The SARS-CoV-2 Spike is a virulence determinant and plays a major role on the attenuated phenotype of Omicron virus in a feline model of infection

Martins, M., Nooruzzaman, M., Cunningham, J. L., Ye, C., Caserta, L. C., Jackson, N. D., Martínez‐Sobrido, L., Fāng, Y., & Diel, D. G. (2024) · Journal of Virology · doi:10.1128/jvi.01902-23 · Cited by 5

Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccinePreprint

Arunachalam, P. S., Feng, Y., Ashraf, U., Hu, M., Edara, V. V., Zarnitsyna, V. I., Aye, P. P., Golden, N., Green, K. M., Threeton, B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.18.484950 · Cited by 5

Memory B cell development in response to mRNA SARS-CoV-2 and nanoparticle immunization in mice

Wiatr, M., wang, Z., Canis, M., Hernandez, B., Gazumyan, A., Santos, G. S. S., Shawraz, S., lee, S., Bieniasz, P. D., Hatziioannou, T., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2527869123 · Cited by 4

Multilayer factors associated with excess all-cause mortality during the omicron and non-omicron waves of the COVID-19 pandemic: time series analysis in 29 countries

Zou, F., Xiao, J., Jin, Y., Jian, R., Hu, Y., Liang, X., Ma, W., & Zhu, S. (2024) · BMC Public Health · doi:10.1186/s12889-024-17803-8 · Cited by 4

Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients

Ferreira, V. H., Hu, Q., Kurtesi, A., Solera, J. T., Ierullo, M., Gingras, A., Kumar, D., & Humar, A. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2022.10.004 · Cited by 4

Evaluation of Potential Peptide‐Based Inhibitors against SARS‐CoV‐2 and Variants of Concern

Boshah, H., Samkari, F., Valle-Pérez, A. U., Alsawaf, S. M., Aldoukhi, A. H., Bilalis, P., Alshehri, S., Susapto, H. H., & Hauser, C. A. E. (2023) · BioMed Research International · doi:10.1155/2023/3892370 · Cited by 4

Post-recovery enhancement of anti-variant neutralisation after severe COVID-19

Lü, Y., Zhu, Y., Cui, M., Cheng, Z., & Peng, H. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00032-5 · Cited by 4

To be remembered: B cell memory response against SARS‐CoV ‐2 and its variants in vaccinated and unvaccinated individuals

Ahmed, N., Athavale, A., Tripathi, A. H., Subramaniam, A., Upadhyay, S. K., Pandey, A. K., Rai, R. C., & Awasthi, A. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13345 · Cited by 4

The Cross-Protective Immunity Landscape Among Different SARS-CoV-2 Variant RBDs

Sun, W., He, L., Lou, H., Fan, W., Yang, L., Cheng, G., Liu, W., & Sun, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898520 · Cited by 4

Real-World Immunogenicity and Reactogenicity of Two Doses of Pfizer-BioNTech COVID-19 Vaccination in Children Aged 5–11 Years

Joseph, G., Klein, E., Lustig, Y., Weiss-Ottolenghi, Y., Asraf, K., Indenbaum, V., Amit, S., Kriger, O., Gilboa, M., Levy, Y., et al. (2022) · Vaccines · doi:10.3390/vaccines10111954 · Cited by 5

Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dosePreprint

Faustini, S. E., Shields, A. M., Banham, G. D., Wall, N. A., Al‐Taei, S., Tanner, C., Ahmed, Z., Efstathiou, E., Townsend, N., Plant, T. D., et al. (2022) · medRxiv · doi:10.1101/2021.12.30.21268308 · Cited by 4

A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and OmicronPreprint

Yuan, T. Z., Lucas, C. G. D. O., Monteiro, V. S., Iwasaki, A., Yang, M. L., Nepita, H. F., Hernández, A. G., Taft, J. M., Frei, L., Reddy, S. T., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.04.474803 · Cited by 4

The Future of SARS-CoV-2 Vaccination

Bachmann, M. F., Mohsen, M. O., & Speiser, D. E. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119437 · Cited by 4

Evolution of Long-Term Hybrid Immunity in Healthcare Workers after Different Covid-19 Vaccination Regimens: A Longitudinal Observational Cohort StudyPreprint

Moore, S. C., Kronsteiner, B., Longet, S., Adele, S., Deeks, A. S., Liu, C., Dejnirattisai, W., Silva-Reyes, L., Meardon, N., Faustini, S. E., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4180810 · Cited by 5

A public health perspective of SARS-CoV-2 evolution and surveillance strategies in Germany from 2020 to 2023

Oh, D., Hölzer, M., Börnigen, D., Paraskevopoulou, S., Duwe, S. C., Budt, M., Kerber, R., Mikołajewska, A., Böttcher, S., Seifried, J., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01093-1 · Cited by 4

Serological insights from SARS-CoV-2 heterologous prime and boost responses in Thailand

Ward, D., Pattarapreeyakul, L., Pitaksalee, R., Thawong, N., Sawaengdee, W., Tuntigumthon, S., Patterson, C., Tetteh, K. K. A., Campino, S. G., Dhepakson, P., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84392-2 · Cited by 3

Longitudinal Innate and Heterologous Adaptive Immune Responses to SARS‐CoV‐2 JN.1 in Transplant Recipients With Prior Omicron Infection: Limited Neutralization but Robust CD4+ T‐Cell Activity

Ferreira, V. H., Keith, B., Mavandadnejad, F., Ferro, A., Marocco, S., Amidpour, G., Kurtesi, A., Qi, F., Gingras, A., Hall, V. G., et al. (2025) · Transplant Infectious Disease · doi:10.1111/tid.70067 · Cited by 3

Association between SARS-CoV-2 Symptoms, Ct Values, and Serological Response in Vaccinated and Unvaccinated Healthcare Personnel

Farnsworth, C. W., O’Neil, C. A., Dalton, C., McDonald, D., Vogt, L. C., Hock, K. G., Arter, O. G., Wallace, M. A., Muenks, C. E., Amor, M., et al. (2023) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfad042 · Cited by 3

Low antibody levels associated with significantly increased rate of SARS‐CoV‐2 infection in a highly vaccinated population from the US National Basketball Association

Tai, C. G.-L., Haviland, M. J., Kissler, S. M., Lucia, R. M., MERSON, M. H., Maragakis, L. L., Ho, D. D., Anderson, D. J., DiFiori, J. P., Grubaugh, N. D., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29505 · Cited by 3

Dynamics of anti-spike IgG antibody after a third BNT162b2 COVID-19 vaccination in Japanese health care workers

Ikezaki, H., Nomura, H., & Shimono, N. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12125 · Cited by 3

Humoral Responses in the Omicron Era following Three-Dose SARS-CoV-2 Vaccine Series in Kidney Transplant RecipientsPreprint

McEvoy, C. M., Hu, Q., Abe, K. T., Yau, K., Oliver, M. J., Levin, A., Gingras, A., Hladunewich, M., & Yuen, D. A. (2022) · medRxiv · doi:10.1101/2022.06.24.22276144 · Cited by 3

Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agentsPreprint

Zhang, F., Jenkins, J., de Carvalho, R. A., Nakandakari-Higa, S., Chen, T., Abernathy, M. E., Nyakatura, E. K., Andrew, D. P., Lebedeva, I., Lorenz, I. C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.24.505169 · Cited by 3

Molecular fate-mapping of serum antibodies reveals the effects of antigenic imprinting on repeated immunizationPreprint

Schiepers, A., Wout, M. F. L. V. ’., Greaney, A. J., Zang, T. M., Muramatsu, H., Lin, P. J. C., Tam, Y. K., Mesin, L., Starr, T. N., Bieniasz, P. D., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.29.505743 · Cited by 3

Immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccines in healthy adults

Wu, Y., Huang, P., Xu, M., Zhao, Q., Xu, Y., Han, S., Li, H., & Wang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152899 · Cited by 3

Antibody titers of individuals vaccinated for COVID-19: A systematic review

Domado, A. M., Adaza, H. J. F., Beltran, A. P. N. C., Buenviaje, L. M., Co, C. D., Combalicer, L. R., Corona, S. M., Cruz, J. B. F., Dinjotian, M. A. C. G., Esperanzate, E. M. S., et al. (2023) · Journal of Biosciences · doi:10.1007/s12038-023-00355-1 · Cited by 2

Analytical Modelling of Inhomogeneous Energy Density Driven (IEDD) Instability in a Magnetized Dusty Plasma Cylinder

Anshu, A., Sharma, J., & Sharma, S. C. (2023) · Brazilian Journal of Physics · doi:10.1007/s13538-023-01383-w · Cited by 2

Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

Gagné, M., Flynn, B. J., Honeycutt, C. C., Flebbe, D. R., Andrew, S. F., Provost, S. J., McCormick, L., Ry, A. V., McCarthy, E. E., Todd, J.-P. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51046-w · Cited by 3

Construction and immunogenicity of recombinant Lactiplantibacillus plantarum vaccine candidate expressing SARS-CoV-2 Omicron S1 protein

Zhang, G., Hao, J., Li, L., Jiang, Y., Hao, P., Yu, J., Ren, L., Li, C., & Wang, M. (2025) · Animals and zoonoses. · doi:10.1016/j.azn.2025.02.001 · Cited by 2

Repeated vaccination with homologous influenza hemagglutinin broadens human antibody responses to unmatched flu viruses

Deng, Y., Tang, M., Ross, T. M., Schmidt, A. G., Chakraborty, A. K., & Lingwood, D. (2025) · eLife · doi:10.7554/elife.107042 · Cited by 4

Effects of the second dose of COVID-19 vaccines in patients with autoimmune rheumatic diseases with hybrid immunity

Menon, A. R., Cherian, S., Paul, A., Kumar, K., Ahmed, S., Mehta, P., Musthafa, S., Gayathri, B., Benny, L., & Shenoy, P. D. (2022) · Rheumatology International · doi:10.1007/s00296-022-05265-3 · Cited by 2

Impact of Mutations in the SARS-CoV-2 Spike RBD Region of BA.1 and BA.2 Variants on its Interaction with ACE2 Receptor Protein

(2022) · Biointerface Research in Applied Chemistry · doi:10.33263/briac134.358 · Cited by 4

Anticuerpos IgG determinados mediante ELISA desarrollados con antígenos de linajes Wuhan y Lambda en trabajadores de salud vacunados con BBIBP-CORV

García-Mendoza, M., Merino-Sarmiento, N. S., Lucio-Burga, G. D., Fernández-Navarro, M., Pampa-Espinoza, L., Solis, G., Huaringa, M., Palomino, M., Rios, P., & Solari, L. (2022) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2022.393.10875 · Cited by 3

Neutralization Effect of Sera against Delta and Omicron in Patients Recovering from COVID-19 and Inactivated Vaccine Recipients

Zhu, Y., Zhong, Q., Ma, Z., Liu, S., Lan, Y., Peng, B., Zhang, X., Shi, X., Qu, J. T., Wu, Z., et al. (2023) · Vaccines · doi:10.3390/vaccines11020471 · Cited by 2

Comparative Pharmacological Efficacy of COVID-19 Vaccines against the Variants of Concerns (VOCs) of SARS-CoV-2: Recent Clinical Studies on Booster Dose

Zhao, D., Wang, X., Liu, J., Chinnappa, A. U., Basavaraj, V., Sri, C. D., Nikolenko, V. N., Beeraka, N. M., Shivaprakash, P., & Fan, R. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666230227115329 · Cited by 2

Bioinformatic analysis of B and T cell epitopes from SARS-CoV-2 Spike, Membrane and Nucleocapsid proteins as a strategy to assess possible cross-reactivity between emerging variants, including Omicron, and other human coronavirusesPreprint

Pacheco-Olvera, D. L., Remy-Hernández, S. S., García-Valeriano, M. G., Rivera-Hernández, T., & López-Macías, C. I. R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.16.480759 · Cited by 2

Immunity Escape of SARS-CoV-2 Variants: Omicron Leads the WayPreprint

Dhingra, R., Sharma, A., Balda, S., Billa, A., Sah, S. N., Capalash, N., & Sharma, P. (2022) · Preprints.org · doi:10.20944/preprints202203.0376.v1 · Cited by 1

Potency and Breadth of Neutralization after 3 doses of mRNA vaccines in COVID-19 Convalescent and Naïve individualsPreprint

Luczkowiak, J., Rivas, G., Labiod, N., Lasala, F., Rolo, M., Lora‐Tamayo, J., Mancheño‐Losa, M., Rial‐Crestelo, D., Pérez‐Rivilla, A., Folgueira, M. D., et al. (2022) · medRxiv · doi:10.1101/2022.03.17.22272557 · Cited by 2

Effectiveness of Vaccination Against SARS-CoV-2 Omicron Variant Infection, Symptomatic Disease, and Hospitalisation: A Systematic Review and Meta-AnalysisPreprint

Meggiolaro, A., Schepisi, M. S., Farina, S., Castagna, C., Mammone, A., Siddu, A., Stefanelli, P., Boccia, S., & Rezza, G. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4147520 · Cited by 2

Ad26.COV2.S priming provides a solid immunological base for mRNA-based COVID-19 booster vaccinationPreprint

Geers, D., Sablerolles, R. S. G., van Baarle, D., Kootstra, N. A., Rietdijk, W. J. R., Schmitz, K. S., Bogers, S., Gommers, L., Nieuwkoop, N. J., van Dijk, L. L. A., et al. (2022) · medRxiv · doi:10.1101/2022.07.15.22277639 · Cited by 2

Defining a highly conserved B cell epitope in the receptor binding motif of SARS-CoV-2 spike glycoproteinPreprint

Malladi, S. K., Jaiswal, D., Ying, B., Alsoussi, W. B., Darling, T. L., Dadonaite, B., Civljak, A., Horvath, S. C., Zhou, J. Q., Kim, W., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.06.625234 · Cited by 2

A epidemia de COVID-19 foi síncrona no espaço? Uma análise nas regiões de saúde do estado do Rio de Janeiro, 2020-2022

Amaral, L. D. F., Lana, R. M., & Bastos, L. S. (2024) · Revista Brasileira de Epidemiologia · doi:10.1590/1980-549720240010 · Cited by 1

NIEAs elicited by wild-type SARS-CoV-2 primary infection fail to enhance the infectivity of Omicron variants

Gui, Q., Wang, H., Liu, C., Li, W., Zhou, B., Tang, S., Fan, Q., Ge, X., Ju, B., & Zhang, Z. (2025) · Virology Journal · doi:10.1186/s12985-025-02667-0 · Cited by 1

Patterns and functional consequences of antibody speciation in maternal-fetal transfer of coronavirus-specific humoral immunity

Hederman, A. P., Brookes, H. M., Natarajan, H., Heyndríckx, L., Ariën, K. K., Weiner, J. A., Rottenstreich, A., Zarbiv, G., Wolf, D. G., Goetghebuer, T., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013408 · Cited by 2

Longitudinal Antibody Dynamics Following SARS-CoV-2 Viral-Vectored and mRNA Booster Vaccination in Ghanaian Adults

Partey, F. D., Mohammed, H., Osei, F., Pobee, A. N. A., Atta-Poku, D. E., Ansah, Y. A. A., Owusu-Amponsah, M. M. A. K., Appiah, N. Y. A., Koranteng, N. A. O., Appiagyei-Mintah, E., et al. (2026) · Vaccines · doi:10.3390/vaccines14040303 · Cited by 1

Structural and functional dissection of neutralisation differences among SARS-CoV-2 variants using antigenicity prediction and CR3022 binding analysis

Sawant, J., Patil, A. A., Thakar, M. R., & Kurle, S. N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1810369 · Cited by 1

Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan

Okumura, N., Tsuzuki, S., Saito, S., Hattori, S.-I., Takeuchi, J. S., Saito, T., Ujiie, M., Hojo, M., Iwamoto, N., Sugiura, W., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2022.04.018 · Cited by 1

SARS-CoV-2 Infections in Vaccinated and Unvaccinated Populations in Camp Lemonnier, Djibouti, from April 2020 to January 2022

Arnold, C. E., Voegtly, L. J., Stefanov, E. K., Lueder, M. R., Luquette, A. E., Miller, R. H., Miner, H. L., Bennett, A. J., Glang, L. A., McGinnis, T. N., et al. (2022) · Viruses · doi:10.3390/v14091918 · Cited by 3

Inactivated vaccine fueled adaptive immune responses to Omicron in 2‐year COVID‐19 convalescents

Liu, M., Zhang, J., Li, L., Li, L., Yang, M., Shang, B., Wang, X., Tian, J., Li, H., Li, H., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28998 · Cited by 1

The Science and the Potential Dangers behind RNA-based Vaccine Technology

Palacios-Castrillo, R. (2023) · Virology & Immunology Journal · doi:10.23880/vij-16000333 · Cited by 1

Long-term analysis of humoral responses and spike-specific T cell memory to Omicron variants after different COVID-19 vaccine regimens

Ho, C.-L., Yen, L.-C., Huang, H., Lu, C., Hung, Y., Liao, C., Hung, C.-M., & Chiu, K. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340645 · Cited by 1

Immunological Response to Subcutaneous and Intranasal Administration of SARS-CoV-2 Spike Protein in Mice

Kinoshita, M., Muranishi, K., Kawaguchi, K., Sudo, K., Inoue, K., Ishikura, H., & Sawa, T. (2024) · Vaccines · doi:10.3390/vaccines12040343 · Cited by 2

Unraveling the tapestry: Immune imprinting amidst a spectrum of challenges for modRNA Covid-19 vaccines

castrillo, R. P. (2024) · African Research Journal of Medical Sciences · doi:10.62587/afrjms.1.1.2024.25-28 · Cited by 1

Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection

Holder, K. A., Ings, D. P., Fifield, K. E., Barnes, D. A., Barnable, K. A., Harnum, D. O. A., Russell, R. S., & Grant, M. D. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400250 · Cited by 1

El enigma del coronavirus – El avance de la variante ómicron – La deltacron

Romero, J. P. (2022) · Revista Peruana de Ginecología y Obstetricia · doi:10.31403/rpgo.v68i2388 · Cited by 1

The genomic and clinical features of the COVID-19 Omicron variant: a narrative review

Hertanto, D. M., Sutanto, H., Lusida, M. I., Kuntaman, K., & Santoso, D. (2022) · F1000Research · doi:10.12688/f1000research.110647.1 · Cited by 2

Preparedness for further boosting coronavirus disease 2019 vaccines

Lim, S. Y., Jung, J., & Kim, S. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.55

Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination

Alidjinou, E. K., Demaret, J., Corroyer-Simovic, B., Vuotto, F., Miczek, S., Labreuche, J., Goffard, A., Trauet, J., Lupau, D., Dendooven, A., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.10.014 · Cited by 1

Evaluation of Four Strategies for SARS-CoV-2 Detection: Characteristics and Prospects

Chen, Y., Ma, Y., Han, Y., Diao, Z., Lu, C., Li, J., & Zhang, R. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02143-22 · Cited by 1

Pilot Study for Immunogenicity of SARS-CoV-2 Vaccine with Seasonal Influenza and Pertussis Vaccines in Pregnant Women

Shen, C., Lin, Y.-P., Hu, S.-Y., Shen, C., Chuang, H., Ker, C.-R., Sun, D.-J., Yang, Y.-H., & Cheng, C. (2023) · Vaccines · doi:10.3390/vaccines11010119 · Cited by 1

Vaccine-induced neutralizing antibodies against SARS-CoV-2 Omicron variant isolated in Osaka, Japan

Hiroi, S., Morikawa, S., Motomura, K., & Mori, H. (2023) · Access Microbiology · doi:10.1099/acmi.0.000465.v3

SARS-CoV-2 specific T cells induced by both SARS-CoV-2 infection and mRNA vaccination broadly cross-recognize omicronPreprint

Lang‐Meli, J., Luxenburger, H., Wild, K., Karl, V., Oberhardt, V., Alizei, E. S., Graeser, A., Reinscheid, M., Roehlen, N., Giese, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1269004/v1 · Cited by 1

Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variantsPreprint

Wang, E. J. D., & Chakraborty, A. K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.24.477469 · Cited by 1

Low Antibody Titers Demonstrate Significantly Increased Rate of SARS-CoV-2 Infection in a Highly Vaccinated Population from the National Basketball AssociationPreprint

Tai, C. G.-L., Haviland, M. J., Kissler, S. M., Lucia, R. M., MERSON, M. H., Maragakis, L. L., Ho, D. D., Anderson, D. J., DiFiori, J. P., Grubaugh, N. D., et al. (2023) · medRxiv · doi:10.1101/2023.02.10.23285780 · Cited by 1

RBD-based high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airwaysPreprint

Gagné, M., Flynn, B. J., Honeycutt, C. C., Flebbe, D. R., Andrew, S. F., Provost, S. J., McCormick, L., Ry, A. V., McCarthy, E. E., Todd, J.-P. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.09.544432 · Cited by 1

Longitudinal analysis of B- and T-cell responses to SARS-CoV-2 recombinant S-protein vaccine S-268019-b in phase 1/2 priming and booster studyPreprint

Fujitani, M., Lu, X., Shinnakasu, R., Inoue, T., Kidani, Y., Seki, N. M., Ishida, S., Mitsuki, S., Ishihara, T., Aoki, M., et al. (2024) · medRxiv · doi:10.1101/2024.10.01.24314659 · Cited by 1

Comparison of vaccine efficacy must be based on good clinical data–Authors’ reply

Taib, N. A. A., Raja, D. B., Teo, A. K. J., Kamarulzaman, A., William, T., Arvinder-Singh, H. S., Mokhtar, S. A., Ting, C., Yap, W. A., Chan, M. Y. K., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100413

What does the omicron variant bring us?

Falcón, H. C. (2022) · Revista Virtual de la Sociedad Paraguaya de Medicina Interna · doi:10.18004/rvspmi/2312-3893/2022.09.01.09

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.033 · Cited by 1,045

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant

Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L. E., & Klein, F. (2022) · Nature Medicine · doi:10.1038/s41591-021-01676-0 · Cited by 410

Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection

Evans, J. P., Zeng, C., Carlin, C., Lozanski, G., Saif, L. J., Oltz, E. M., Gumina, R. J., & Liu, S. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn8057 · Cited by 239

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

Sievers, B. L., Chakraborty, S., Xue, Y., Gelbart, T., Gonzalez, J. C., Cassidy, A. G., Golan, Y., Prahl, M., Gaw, S. L., Arunachalam, P. S., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn7842 · Cited by 111

Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant

Lyke, K. E., Atmar, R. L., Islas, C. D., Posavad, C. M., Szydlo, D., Paul Chourdhury, R., Deming, M. E., Eaton, A., Jackson, L. A., Branche, A. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100679 · Cited by 153